Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying an investigational drug called linvoseltamab in adults who have a moderate risk of developing multiple myeloma. This group includes patients with precancerous conditions known as High-Risk Monoclonal Gammopathy of Undetermined Significance HR-MGUS and Non-High-Risk Smoldering Multiple Myeloma NHR-SMM. The main goal is to understand how well linvoseltamab can eliminate abnormal plasma cells and laboratory signs associated with these conditions. Participants will receive linvoseltamab following a step-up dosing regimen to assess safety and tolerability before moving to one of four full dosing regimens. The study is divided into a safety run-in phase and an expansion phase where participants are assigned to different dose groups without randomization. Linvoseltamab is given according to the study protocol, with dosing schedules designed to monitor effects and side effects. During the study, participants will be closely monitored through regular safety observations over 35 days and longer-term assessments up to 5.5 years. Researchers will track adverse events, treatment responses including complete response rates, laboratory results, and the presence of antibodies against the drug. Blood levels of linvoseltamab are measured up to 9 months. This comprehensive monitoring will help understand the drugs impact and safety over time.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are evaluating an experimental drug called odronextamab in adults with previously untreated follicular lymphoma, a type of non-Hodgkin lymphoma. The study consists of two parts Part 1 focuses on assessing the safety and tolerability of odronextamab alone, while Part 2 compares odronextamab to rituximab combined with chemotherapy, which is the current standard treatment. The research also explores side effects, drug levels in the blood, immune responses against the drug, and effects on quality of life and daily activities. Participants in Part 1 receive only odronextamab. In Part 2, participants are randomly assigned to one of two groups one group receives odronextamab followed by maintenance treatment with the same drug, and the other group receives rituximab combined with chemotherapy followed by rituximab maintenance. Chemotherapy options include combinations of cyclophosphamide, doxorubicin, vincristine, prednisone, and bendamustine, administered as described in the study protocol. Throughout the study, participants undergo regular assessments including imaging scans to measure disease, blood tests to monitor drug levels and immune response, and evaluations of physical function and quality of life. Researchers track adverse events and treatment responses up to five years. Safety and effectiveness are closely monitored, with key outcomes measured at intervals up to 30 months and beyond. The total participation time varies depending on treatment and follow-up schedules.
Actively Recruiting
Researchers are evaluating whether the antiarrhythmic drug flecainide is as safe as standard rhythm-control drugs sotalol or amiodarone in adults aged 18 years and older who have atrial fibrillation AF with stable coronary artery disease CAD. The study aims to determine if flecainide leads to similar or fewer serious side effects, hospitalizations, or deaths compared to standard treatments. This Phase 4 randomized trial compares these treatments in patients with documented AF and stable CAD. Participants are randomly assigned to receive either flecainide or standard rhythm-control medication sotalol or amiodarone as part of their routine clinical care. Flecainide dosing starts at 100 to 150 mg per day, taken in divided doses or once daily with controlled release, combined with an AV nodal blocker. Sotalol dosing starts at 80 mg twice daily, with adjustments for kidney function, while amiodarone treatment involves a loading phase followed by maintenance dosing. Treatment follows physician preference and patient needs. During the study, participants attend regular hospital visits and telephone follow-ups. They undergo routine heart tests including electrocardiograms and echocardiography, and complete questionnaires about symptoms, quality of life, and daily functioning. Researchers monitor safety outcomes, heart rhythm, healthcare use, and quality of life for at least one year. The main outcome measured is a composite safety outcome after one year of treatment.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are evaluating the potential benefits of an oral formulation based on Cetylated Fatty Acids in helping heal fractures of long bones in the lower limbs, such as the femur or tibia. This clinical trial is randomized, double-blind, and placebo-controlled, aiming to support the early stage of bone healing after surgical stabilization of these fractures. The study is sponsored by Pharmanutra S.p.a. and involves adults aged 18 to 85 years. Participants will take two sachets of the assigned oral product daily for at least 12 weeks, starting from the baseline visit after all initial procedures are completed. There are two study groups one receiving the CFA-based food supplement and the other receiving a placebo gel matched in color and flavor. The intake continues until the morning of the last study visit Visit 3. Throughout the study, participants will undergo standard imaging tests like radiography and ultrasound to assess bone healing. Blood samples will be collected, and participants will complete quality of life questionnaires such as the Short Form-36. Researchers will measure callus formation using the modified Radiographic Union Score for Tibia mRUST and monitor pain levels, complications, medication use, and participant satisfaction at 4, 6, and 12 weeks after fracture stabilization. Adherence to the supplement and any adverse events will also be tracked during the trial.
Actively Recruiting
Researchers are evaluating a structured, evidence-based rehabilitation pathway called the R pathway for patients undergoing lumbar surgery due to radicular pain. This multicenter cluster randomized controlled trial compares the R pathway against usual care to see if it can reduce the time it takes for patients to return to work after surgery. The study focuses on patients aged 18 to 65 scheduled for lumbar spinal surgery with radicular pain lasting at least six weeks. The R rehabilitation pathway involves coordinated care guided by a case manager, starting before surgery and continuing up to one year afterward. It includes prehabilitation, perioperative rehabilitation, and postoperative rehabilitation, aiming to reduce fear by minimizing unnecessary activity restrictions, eliminating bracing, and actively encouraging return to work. Hospitals are randomized to either implement the R pathway or continue with their usual variable rehabilitation care, which may include no rehabilitation or various types of therapy. Participants will be monitored from surgery through 15 months postoperatively. Researchers will assess the time to return to work as the primary outcome. Secondary outcomes include disability, percentage of patients returned to work, functional status, back and leg pain, health-related quality of life, work productivity, analgesic use, kinesiophobia, and pain catastrophizing at multiple time points. The study requires written consent and involves follow-up assessments to evaluate recovery and work reintegration.
Actively Recruiting
Researchers are collecting detailed data about suicide attempts and suicidal thoughts among people who come to healthcare services in Flanders. The study aims to understand how often these behaviors occur, the methods used, and how many receive proper follow-up care after a suicide attempt. This observational study uses a structured interview tool called the Guideline for Suicide Care and Evaluation LOES to gather comprehensive information. Participants undergo a two-part semi-structured interview administered by trained nurses, psychologists, or psychiatrists. The first part happens soon after admission to a healthcare facility and collects information on emotional state, mental health history, social support, hopelessness, and suicidal behavior. The second part provides a deeper evaluation of risk factors, treatment needs, motivations, planning, and coping strategies related to suicidality. Throughout the study, participants provide demographic, clinical, and psychological information through interviews. Researchers assess suicidal intent, planning, past behavior, substance use risk, and care needs. The study tracks treatment agreements and care pathways after assessment. Data collection occurs at the initial presentation, with no drug or medical treatment being tested. The total participation time varies depending on the individuals healthcare encounters and follow-up.